

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14875-137US1	Application No. 10/516,603
	Applicant Tatsuhiko Kodama et al.		
	Filing Date June 8, 2005	Group Art Unit 1632	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
/M.N./	A1	Campbell, "Monoclonal antibody technology", Elsevier Science Publishing Company Inc., pp. 1-33. (1984)
/M.N./	A2	D'Onofrio, "Making the case for cancer prevention in the schools", <i>Journal of School Health</i> , 225-231 (1989).
/M.N./	A3	Inoue <i>et al.</i> , "Regulation of human peptide transporter 1 (PEPT1) in gastric cancer cells by anticancer drugs", <i>Cancer Letters</i> , 230:72-80 (2005).
/M.N./	A4	Pardee, "Tumor progression – targets for differential therapy", <i>Journal of Cellular Physiology</i> , 209:589-591 (2006).
/M.N./	A5	Winter <i>et al.</i> , "Man-made antibodies", <i>Nature</i> , 349:293-299 (1991).

Examiner Signature	Marcia Noble <small>Digitally signed by Marcia Noble DN: cn=Marcia Noble, email=marcia.noble@uspto.gov, o=USPTO, ou=REGISTRATION, c=US</small> /Marcia Noble/	Date Considered	09/16/2008
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			